Linezolid for patients with neutropenia: Are bacteriostatic agents appropriate?

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 4, 2009, Pages 415-422

  Rafailidis, Petros I ^a,b   Kouranos, Vasilios D ^a   Christodoulou, Christos ^a,c   Falagas, Matthew E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; GRAM POSITIVE INFECTION; HUMAN; MORTALITY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PROGNOSIS; THROMBOCYTOPENIA; VOMITING; ADULT; BACTERIAL INFECTION; FEMALE; MALE; REVIEW;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NEUTROPENIA; OXAZOLIDINONES; PROGNOSIS;

EID: 85047683453     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.11     Document Type: Article

References (28)

1. Klastersky J, Paesmans M, Georgala A et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J. Clin. Oncol. 24, 4129-4134 (2006).
2. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5, 431-439 (2005).
3. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730-751 (2002).
4. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38, 864-870 (2004).
5. Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG. Oxazolidinones: a new class of antibacterials. Curr. Opin. Pharmacol. 1, 470-476 (2001).
6. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistanc enterococci. Diagn. Microbiol. Infect. Dis. 30, 109-112 (1998).
7. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839-845 (1996).
8. Zyvox® package insert, Pfizer (distributed by Pharmacia & Upjohn Company, NY, USA, 10017).
9. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38, 17-24 (2004).
10. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res. Clin. Pract. 80(3), 344-531 (2008).
11. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. 42, 597-607 (2006).
12. Raad I, Hachem R, Hanna H et al. Prospective, randomized study comparing quinupristin - dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J. Antimicrob. Chemother. 53, 646-649 (2004).
13. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann. Oncol. 14, 795-801 (2003).
14. Avery R, Kalaycio M, Pohlman B et al. Early vancomycin-resistant Enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 35, 497-415 (2005).
15. Weinstock DM, Conlon M, Iovino C et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant Enterococcus early after allogeneic hematopoietic stem cell transplant. Biol. Blood Marrow Transplant. 13, 615-621 (2007).
16. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin. Infect. Dis. 30, 146-151 (2000).
17. Dibo I, Pillai SK, Gold HS et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J. Clin. Microbiol. 42, 1843-1845 (2004).
18. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin. Proc. 80, 1215-1216 (2005).
19. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/ dalfopristin). Clin. Infect. Dis. 30, 403-404 (2000).
20. Mehta S, Johnson J, Venezia R, Forrest G. Emergence of linezolid-resistant enterococci in a neutropenic patient. J. Hosp. Infect. 62, 125-127 (2006).
21. Miura Y, Kami M, Kusumi E et al. Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen. Am. J. Hematol. 81, 222-224 (2006).
22. Verma N, Clarke RW, Bolton-Maggs PHB, van Saene HKF. Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report. J. Pediatr. Hematol. Oncol. 29, 557-560 (2007).
23. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. 58, 273-280 (2006).
24. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int. J. Antimicrob. Agents 29, 233-239 (2007).
25. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann. Pharmacother. 41, 296-308 (2007).
26. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin. Pharmacother. 8, 2381-2400 (2007).
27. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J. Antimicrob. Chemother. 50, 665-672 (2002).
28. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect. Dis. 8, 53-66 (2008).